Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | CPA1 | P15085 | 1/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.50 |
| ▸ | ENPEP | Q07075 | 15/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30051636 | 0.97 | MME (0.53) | MMEACECPA1ACE2ENPEP | |
| SCHEMBL30592759 | 0.91 | ALDH1A1 (0.50) | ENPEPCTSDALDH1A1 | |
| SCHEMBL30592754 | 0.91 | CTSD (0.47) | ENPEPCTSDALDH1A1 | |
| SCHEMBL30052603 | 0.91 | MME (0.53) | MMEACECPA1ACE2ENPEP | |
| SCHEMBL30668289 | 0.90 | MME (0.51) | MMEACECPA1ACE2ENPEP | |
| SCHEMBL30051533 | 0.89 | MME (0.54) | MMEACECPA1ACE2ENPEP | |
| SCHEMBL30051530 | 0.89 | ALDH1A1 (0.51) | ENPEPCTSDALDH1A1 | |
| SCHEMBL30051960 | 0.89 | ALDH1A1 (0.47) | ENPEPCTSDALDH1A1 | |
| SCHEMBL30592756 | 0.89 | ALDH1A1 (0.47) | ENPEPCTSDALDH1A1 | |
| SCHEMBL8278141 | 0.89 | DPP4 (0.47) | MMEACECPA1ACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | disclosed |
| US-20250263397-A1 | CRYSTALLINE PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHIC FORM OF THE GLUTAMINYL CYCLASE INHIBITOR VAROGLUTAMSTAT | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-21 | — | — | US | disclosed |
| US-12384772-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-12 | — | — | US | disclosed |
| US-12312335-B1 | Crystalline pharmaceutically acceptable salt and polymorphic form of the glutaminyl cyclase inhibitor Varoglutamstat | VIVORYON THERAPEUTICS N.V. (DE) | 2025-05-27 | — | — | US | disclosed |
| US-12043659-B2 | Humanized and de-immunized antibodies | VIVORYON THERAPEUTICS N.V. (DE) | 2024-07-23 | — | — | US | disclosed |
| US-20220274977-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | GLS, GLS2, SULT1E1 | MME 2267/4885ACE 777/4885CPA1 1797/4885 |
| US-12312335-B1 | Crystalline pharmaceutically acceptable salt and polymorphic form of the glutaminyl cyclase inhibitor Varoglutamstat | QPCT, GLS, QPCTL | MME 3905/4885ACE 390/4885CPA1 1276/4885 |
| US-20250263397-A1 | CRYSTALLINE PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHIC FORM OF THE GLUTAMINYL CYCLASE INHIBITOR VAROGLUTAMSTAT | QPCT, GLS, QPCTL | MME 3905/4885ACE 390/4885CPA1 1276/4885 |
| US-12384772-B2 | Inhibitors | GLS, QPCT, GLS2 | MME 1000/4885ACE 260/4885CPA1 2944/4885 |
| US-20220274977-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | MME 2186/4885ACE 912/4885CPA1 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.